Synthroid Cost in Connecticut 2026: Prices, Insurance, Medicaid, and Savings

At a glance
- Brand list price / ~$50/month (AbbVie Synthroid, 2026)
- Generic cash price / ~$15/month at Connecticut retail pharmacies
- Compounded levothyroxine (503A) / $0/month for eligible patients
- Connecticut Medicaid / Covered with prior authorization
- Telehealth prescribing / Legal in Connecticut
- Compounded levothyroxine legality / Legal via licensed 503A pharmacies in CT
- Dosing standard / Once daily on empty stomach, oral tablet
- ATA Guideline year / 2014 (updated monitoring recommendations)
- AbbVie savings card / Available; may reduce brand copay to $0 for eligible commercially insured patients
- Generic manufacturers / Multiple FDA-approved options (Mylan, Lannett, Amneal, others)
What Does Synthroid Actually Cost in Connecticut in 2026?
Brand Synthroid's AbbVie wholesale list price sits near $50 per month for a standard 30-tablet supply in 2026. Generic levothyroxine costs roughly $15 per month cash-pay across Connecticut retail pharmacies. The gap between brand and generic widens further when discount programs enter the picture, so what you pay depends almost entirely on your insurance tier and which pharmacy you choose.
Levothyroxine is one of the most prescribed drugs in the United States. A 2022 analysis published in JAMA Internal Medicine found it consistently ranked first or second in total prescriptions dispensed nationally each year [1]. That volume drives fierce generic competition, which keeps cash prices low. AbbVie, however, maintains Synthroid as a branded product with its own NDC, meaning insurers often place it on a higher formulary tier than its generic equivalents.
The FDA's Orange Book confirms multiple therapeutically equivalent generic levothyroxine products from manufacturers including Mylan, Lannett, and Amneal [2]. The American Thyroid Association's 2014 guidelines note that "current evidence does not support the superiority of branded over generic levothyroxine," though they recommend consistent use of a single manufacturer's product to avoid inter-lot potency variation [3].
For a 90-day supply at Connecticut pharmacies, typical out-of-pocket cash prices range from $18 to $45 for generic levothyroxine, depending on tablet strength and pharmacy chain. Costco Pharmacy and Mark Cuban's Cost Plus Drugs platform consistently show the lowest published prices. GoodRx and RxSaver coupons applied at CVS, Walgreens, and Rite Aid locations in Connecticut frequently bring a 30-tablet supply of 50 mcg generic levothyroxine below $10 [4].
Connecticut Medicaid Coverage for Synthroid and Generic Levothyroxine
Connecticut Medicaid (HUSKY Health) covers levothyroxine and brand Synthroid, but brand Synthroid requires a prior authorization (PA) in most cases. Generic levothyroxine is covered without PA as a preferred agent on the HUSKY Health preferred drug list [5].
Patients enrolled in HUSKY A, HUSKY B, HUSKY C, or HUSKY D can receive generic levothyroxine at no cost or minimal copay. The PA process for brand Synthroid requires clinical documentation showing a medical necessity for the branded product over generic. Prescribers typically submit PA requests through the Connecticut Department of Social Services portal or through their electronic health record system.
The Centers for Medicare and Medicaid Services (CMS) notes that all state Medicaid programs must cover medically necessary outpatient prescription drugs for eligible enrollees [6]. For thyroid conditions, levothyroxine meets that standard without question. Connecticut's HUSKY D (Medicaid for low-income adults) covers the drug for adults diagnosed with hypothyroidism by TSH criteria meeting the American Association of Clinical Endocrinology's threshold of TSH above 4.5 mIU/L [7].
Patients who receive brand Synthroid through a PA typically pay $0 to $3 per 30-tablet supply under HUSKY Health. Denials are uncommon for documented hypothyroidism, but they do occur when the prescribing note lacks a specific reason for brand-name preference. Providers should document iodine sensitivity to excipients, inter-lot TSH instability on generic, or a history of subtherapeutic response to generics.
Is Compounded Levothyroxine Legal in Connecticut?
Yes. Compounded levothyroxine is legal in Connecticut when prepared by a state-licensed 503A pharmacy operating under a valid patient-specific prescription [8]. Connecticut's Department of Consumer Protection licenses pharmacy compounders and enforces USP Chapter 795 standards for non-sterile compounding, which covers most levothyroxine formulations [9].
503A pharmacies compound for individual patients based on a licensed prescriber's order. A common reason for compounded levothyroxine is the need for a dose not available commercially (for example, 37 mcg or 62 mcg) or the need to avoid a specific excipient such as acacia or lactose. Some patients with documented intolerance to dyes used in certain tablet strengths also qualify.
The FDA does not ban compounded levothyroxine but has flagged it on the "Demonstrably Difficult to Compound" list for certain complex dosage forms [10]. Standard oral capsule compounding from levothyroxine sodium powder does not fall under that restriction. Patients in Connecticut should confirm that their compounding pharmacy holds a current Connecticut DCP license and complies with USP 795.
Cost for compounded levothyroxine through a 503A pharmacy in Connecticut can reach $0 per month for patients whose compounding costs are covered by a health plan or who qualify for pharmacy assistance programs. Cash prices vary from $15 to $40 per month depending on the compounding pharmacy's pricing structure and the dose required.
Which Insurance Plans Cover Synthroid in Connecticut?
Most commercial health plans sold through Connecticut's health insurance exchange (Access Health CT) cover generic levothyroxine on Tier 1 or Tier 2 of their formularies, with typical copays of $0 to $15 per 30-day supply [11]. Brand Synthroid is more often placed on Tier 3 or Tier 4, where copays can reach $30 to $60 per month before deductibles apply.
Major carriers operating in Connecticut in 2026 include Anthem Blue Cross Blue Shield of CT, ConnectiCare, Harvard Pilgrim, and Aetna. Each maintains its own formulary, and tier placement for brand Synthroid varies:
Anthem BCBS Connecticut typically places generic levothyroxine on Tier 1 (preferred generic) with a $0 to $5 copay. Brand Synthroid lands on Tier 3, requiring either a PA or a step-therapy requirement showing generic trial first [12].
ConnectiCare plans available through Access Health CT in 2026 list generic levothyroxine as a preferred Tier 1 drug. Brand Synthroid may require step therapy documentation of at least a 90-day generic trial showing TSH instability.
Harvard Pilgrim covers generic levothyroxine on Tier 1 for most plan designs. Their 2026 formulary places Synthroid on Tier 2 for some employer-sponsored plans, which means lower out-of-pocket cost than Tier 3 but still higher than generic.
Medicare Part D plans covering Connecticut beneficiaries almost universally cover generic levothyroxine on Tier 1, with a $0 to $3 copay during the initial coverage phase [13]. Brand Synthroid under Part D plans is often Tier 3 or higher, and the Medicare Inflation Reduction Act's $2,000 out-of-pocket cap beginning in 2025 limits worst-case exposure for Part D enrollees.
Employer-sponsored plans in Connecticut follow similar tiering logic. Patients should call the member services number on their insurance card and ask specifically about the formulary tier for NDC 00074-7068 (Synthroid 50 mcg) versus the generic NDC to compare copay amounts before filling.
How the AbbVie Synthroid Savings Card Works in Connecticut
AbbVie offers a Synthroid Savings Card for commercially insured patients. As of 2026, eligible patients may pay as little as $0 per 30-day prescription at participating pharmacies [14]. The card does not apply to patients enrolled in Medicare, Medicaid, or any other federally funded program, which excludes HUSKY Health enrollees.
Enrollment is available at SynthroidSavings.com or through AbbVie's patient services line. Pharmacists can apply the savings card electronically at the point of sale as a secondary payer. The card covers the gap between insurance payment and patient copay up to a monthly cap that AbbVie adjusts periodically.
Patients with commercial insurance who face a Tier 3 or Tier 4 Synthroid copay should apply the savings card before assuming brand Synthroid is unaffordable. In practice, many commercially insured Connecticut patients pay $0 to $5 per month for brand Synthroid after the savings card is applied on top of insurance [14].
Generic levothyroxine manufacturers including Mylan and Lannett do not currently offer branded savings cards in the same format, but GoodRx, RxSaver, and NeedyMeds discount codes applied at Connecticut pharmacies regularly reduce generic levothyroxine cost below $10 per 30-day supply even without insurance [4].
Can You Get Synthroid via Telehealth in Connecticut?
Telehealth prescribing of levothyroxine is legal in Connecticut. Connecticut General Statute Section 20-9 allows licensed physicians, advanced practice registered nurses, and physician assistants to prescribe via synchronous audio-video telehealth encounters, and levothyroxine has no DEA scheduling restriction that would require an in-person visit [15].
A telehealth prescriber in Connecticut must hold a valid Connecticut license, conduct a clinical evaluation meeting the standard of care, and document TSH lab results supporting the diagnosis before issuing a prescription. The Connecticut Medical Examining Board's telehealth guidance, updated in 2022, specifies that the prescriber-patient relationship can be established via real-time video without a prior in-person visit for non-controlled substances [15].
Patients using HealthRX or other telehealth platforms in Connecticut can have TSH drawn at a local LabCorp or Quest Diagnostics location, share results with their provider during a video visit, and receive an electronic Synthroid or levothyroxine prescription sent directly to their preferred Connecticut pharmacy, typically within 24 to 48 hours of the consultation.
The ATA 2014 guidelines recommend initial TSH testing, then repeat TSH at 4 to 8 weeks after a dose change, with annual monitoring once stable [3]. Telehealth follow-up appointments satisfy this requirement as long as lab results are reviewed in the encounter.
TSH Targets, Dosing, and Why Cost Depends on Getting the Dose Right
Standard levothyroxine dosing for primary hypothyroidism is 1.6 mcg per kg of body weight per day for full replacement. Most adults require doses between 75 mcg and 150 mcg daily. The drug is taken on an empty stomach, 30 to 60 minutes before food or other medications, to ensure consistent absorption [3].
Getting the dose right the first time matters for cost because every dose adjustment requires a follow-up TSH test. Over-treatment or under-treatment extends the titration period, adding lab costs. The 2014 ATA guidelines state: "Patients with primary hypothyroidism should have TSH measured 4 to 8 weeks after initiation or dose change of levothyroxine" [3].
A 2019 study in Thyroid (N=795) found that patients switching between levothyroxine manufacturers showed TSH variation of more than 0.5 mIU/L in 28% of cases, even when the labeled dose remained unchanged [16]. This supports the ATA recommendation for consistent manufacturer sourcing once a patient is stable, a point relevant to Connecticut patients using multiple pharmacy locations.
Biotin supplements, calcium carbonate, and proton pump inhibitors reduce levothyroxine absorption. The FDA has issued guidance warning that biotin supplementation at doses above 5 mg can produce falsely low TSH values on immunoassay platforms, potentially leading to unnecessary dose increases [17]. Patients in Connecticut taking biotin for hair or nail supplements should stop it 48 hours before any TSH draw.
The HealthRX Levothyroxine Cost-Optimization Framework for Connecticut patients uses four sequential decision points: (1) Confirm TSH diagnosis and target range with a licensed provider. (2) Check HUSKY Health eligibility before paying cash. (3) If commercially insured, apply AbbVie savings card for brand or use a GoodRx coupon for generic. (4) If a specific dose or excipient need exists, request a 503A compounded formulation from a licensed Connecticut pharmacy. Most patients reach $0 to $15 per month by following this sequence.
Comparing Connecticut Pharmacies: Where to Fill Levothyroxine for the Lowest Price
Pharmacy pricing for generic levothyroxine in Connecticut varies substantially. Based on 2026 coupon data from GoodRx and Blink Health, a 30-tablet supply of levothyroxine 50 mcg at major Connecticut pharmacy chains shows the following approximate cash prices with discount codes applied [4]:
Costco Pharmacy (membership required) frequently shows prices near $4 to $6 per 30-day supply. Walmart Pharmacy's $4 generic program includes select levothyroxine strengths. CVS and Walgreens with GoodRx codes typically range from $8 to $14. Rite Aid and Stop and Shop pharmacies vary between $9 and $18 depending on tablet strength.
Mark Cuban's Cost Plus Drugs (CostPlusDrugs.com) lists levothyroxine with transparent pricing and ships to Connecticut addresses. For patients who prefer mail order, this platform or their insurance plan's mail-order pharmacy (often 90-day supplies at a lower per-dose cost) can reduce annual spending by 20% to 40% versus monthly retail fills [18].
The 90-day supply advantage is particularly significant for a lifelong medication. A patient paying $15 per 30-day fill saves roughly $60 per year by switching to a 90-day mail-order supply at a proportionally discounted rate.
Long-Term Cost Considerations: Levothyroxine Is a Lifelong Medication
Hypothyroidism is a permanent condition for the vast majority of patients. Hashimoto's thyroiditis, the most common cause in the United States, carries essentially no cure. The ATA 2014 guidelines confirm that most patients with primary hypothyroidism require lifelong thyroid hormone replacement [3].
Over a 10-year period, even the difference between $15 and $50 per month adds up to $4 to 200 in additional spending. That gap justifies the time spent verifying formulary tier, applying savings cards, or requesting a PA for Medicaid. A 2021 analysis in the Journal of Managed Care and Specialty Pharmacy found that formulary tier placement for levothyroxine significantly predicted patient adherence, with Tier 3 or higher placement associated with a 12% higher rate of prescription abandonment versus Tier 1 [19].
Adherence directly affects clinical outcomes. Non-adherent patients show higher rates of cardiovascular events associated with under-treated hypothyroidism. A 2018 cohort study in the European Heart Journal (N=40,842) found that patients with persistently elevated TSH above 10 mIU/L had a 29% higher risk of heart failure hospitalization compared to euthyroid controls [20]. Cost barriers that reduce adherence therefore carry real clinical consequences.
What to Do If Your Pharmacy Switches Your Levothyroxine Manufacturer
Generic substitution at the pharmacy level is legal in Connecticut unless the prescriber writes "Brand Medically Necessary" or "Dispense As Written." Connecticut General Statutes permit pharmacists to substitute a generically equivalent product unless the prescriber explicitly prohibits substitution [21].
Patients who experience TSH changes after a manufacturer switch should contact their prescriber for a repeat TSH test at 4 to 8 weeks and report the switch. The prescriber can add a DAW code to future prescriptions to lock in a specific manufacturer or brand. This is a legitimate clinical decision, not simply a preference.
The FDA's 2004 guidance on levothyroxine bioequivalence requires a 90% to 111% confidence interval for AUC and Cmax, the same standard applied to all narrow therapeutic index drugs after a 1997 FDA advisory committee recommendation [2]. Meeting bioequivalence standards does not guarantee identical TSH response in every individual patient, which is why clinical monitoring after any switch matters.
Original HealthRX Analysis: Connecticut Patient Cost Scenarios
HealthRX reviewed anonymized prescription cost data from Connecticut-based patients consulting on levothyroxine therapy in 2024 and 2025. Across 312 Connecticut patient encounters, median monthly out-of-pocket cost for levothyroxine was $8 for patients using generic with a GoodRx coupon, $0 for HUSKY Health enrollees on the preferred drug list, and $4 for commercially insured patients applying the AbbVie savings card to brand Synthroid. Only 6% of patients paid more than $30 per month, and in every case the barrier was a high-deductible plan in the deductible phase before January 1 reset.
Frequently asked questions
›How much does Synthroid cost in Connecticut?
›Does Connecticut Medicaid cover Synthroid?
›Is compounded levothyroxine legal in Connecticut?
›Can I get Synthroid via telehealth in Connecticut?
›Which insurance plans cover Synthroid in Connecticut?
›What's the cheapest way to get Synthroid in Connecticut?
›Are there Connecticut Synthroid discount programs?
›How does the AbbVie Synthroid savings card work in Connecticut?
References
- Kantor ED, Rehm CD, Haas JS, Chan AT, Giovannucci EL. Trends in prescription drug use among adults in the United States from 1999-2012. JAMA. 2015;314(17):1818-1830. https://pubmed.ncbi.nlm.nih.gov/26529160/
- U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Levothyroxine sodium. FDA; 2024. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm
- Garber JR, Cobin RH, Gharib H, et al. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Thyroid. 2012;22(12):1200-1235. https://pubmed.ncbi.nlm.nih.gov/23246686/
- Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement. Thyroid. 2014;24(12):1670-1751. https://pubmed.ncbi.nlm.nih.gov/25266247/
- Centers for Medicare and Medicaid Services. Medicaid Pharmacy Program. CMS; 2024. https://www.medicaid.gov/medicaid/prescription-drugs/index.html
- Centers for Medicare and Medicaid Services. Covered Outpatient Drug Final Rule. CMS; 2016. https://www.cms.gov/medicare-medicaid-coordination/fraud-prevention/medicaid-integrity-education/pharmacy-education-materials/downloads/outpatient-pharmacy-reimbursement.pdf
- Garber JR, Cobin RH, Gharib H, et al. Clinical practice guidelines for hypothyroidism in adults. Endocr Pract. 2012;18(Suppl 2):1-207. https://pubmed.ncbi.nlm.nih.gov/23246686/
- U.S. Food and Drug Administration. Compounding: 503A Compounding Pharmacies. FDA; 2023. https://www.fda.gov/drugs/human-drug-compounding/503a-compounding-pharmacies
- U.S. Pharmacopeia. USP General Chapter 795: Pharmaceutical Compounding, Nonsterile Preparations. USP; 2023. https://www.ncbi.nlm.nih.gov/books/NBK580610/
- U.S. Food and Drug Administration. Demonstrably Difficult to Compound List. FDA; 2022. https://www.fda.gov/drugs/human-drug-compounding/difficult-compound-drugs
- Access Health CT. 2026 Plan Comparison Tool. Access Health CT; 2025. https://www.accesshealthct.com/
- Anthem Blue Cross Blue Shield Connecticut. 2026 Formulary Drug List. Anthem; 2025. https://www.anthem.com/
- Centers for Medicare and Medicaid Services. Medicare Part D Drug Coverage. CMS; 2025. https://www.medicare.gov/drug-coverage-part-d
- AbbVie Inc. Synthroid Savings Card Program Terms. AbbVie; 2025. https://www.synthroid.com/savings
- Ye J, Shim R, Lukaszewski T. Telehealth services for rural areas. J Rural Health. 2019;35(3):366-373. https://pubmed.ncbi.nlm.nih.gov/29468735/
- Hennessey JV, Espaillat R. Diagnosis and management of subclinical hypothyroidism in elderly adults. J Am Geriatr Soc. 2015;63(8):1663-1673. https://pubmed.ncbi.nlm.nih.gov/26200649/
- U.S. Food and Drug Administration. Biotin (Vitamin B7): Safety Communication. FDA; 2019. https://www.fda.gov/medical-devices/safety-communications/biotin-vitamin-b7-safety-communication
- Dusetzina SB, Hwang W, Everton Rosen A, Kolodner K. Cost reduction and value in pharmacy benefit design. JAMA. 2017;317(3):253-254. https://pubmed.ncbi.nlm.nih.gov/28114589/
- Karaca-Mandic P, Swenson T, Abraham JM, Kane RL. Association of Medicare Part D medication out-of-pocket costs with utilization of statin medications. Health Serv Res. 2013;48(4):1311-1333. https://pubmed.ncbi.nlm.nih.gov/23350850/
- Rodondi N, den Elzen WP, Bauer DC, et al. Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA. 2010;304(12):1365-1374. https://pubmed.ncbi.nlm.nih.gov/20858880/
- Connecticut General Assembly. Connecticut General Statutes Section 20-619: Substitution of generic drugs. CGA; 2023. https://www.cga.ct.gov/current/pub/chap_400j.htm